Catalyst

Slingshot members are tracking this event:

Discovery Labs (DSCO) to Initiate Phase 2b Trial in Q4 for AEROSURF in Premature Infants 29 to 32 Weeks Gestational Age with Respiratory Distress Syndrome

Source Link:
http://seekingalpha.com/pr/15056666-discovery-labs-announces-completion-of-enrollment-in-aerosurf-phase-2a-dose-expansion-trial

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
DSCO
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details With the completion of enrollment in this trial (the Phase 2a), the Company expects to initiate its AEROSURF phase 2b trial in the fourth quarter of 2015 beginning with premature infants 29 to 32 weeks GA.
http://seekingalpha....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Dec 29, 2015
Occurred Source:
http://windtreetx.investorroom.com/2015-12-29-Discovery-Labs-Announces-Initiation-of-AEROSURF-Phase-2b-Clinical-Trial
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Aerosurf, Respiratory Distress Syndrome, Premature Infants
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.